NV-001 for advanced solid tumors after standard treatments
Part of Cancer clinical trials.
This trial tests a new drug called NV-001 for people with advanced solid tumors that are no longer responding to standard treatments. It aims to see if the drug is safe and can help shrink or slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic solid tumors that have gotten worse after standard treatments, or you can't handle those treatments.
- You are able to get out of bed and take care of yourself (ECOG score 0 or 1) and your doctor expects you to live at least 12 more weeks.
- You have at least one tumor that can be measured on scans and is safe to biopsy (a small needle sample).
- Your blood counts, liver, and kidney function are within certain safe limits.
- You agree to use reliable birth control if you could become pregnant or father a child, and avoid sperm donation for 90 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new drug called JSKN027 for people with advanced solid tumors (cancers that have spread) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
This trial tests a new injection called CEL001 for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if it is safe and find the right dose.
This trial tests a new drug called KH801 for people with advanced solid tumors (cancers that have spread) that haven't been helped by other treatments. The goal is to see if it is safe and how well it works.
This trial tests a new drug called NP-101 for people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and see if it can shrink tumors.
This study tests a new experimental drug (NWY001) for people with advanced solid tumors that have stopped responding to standard treatments. It is a phase 1 trial, meaning it is early research to find the right dose and check for side effects.
Hear when a new Malignant Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.